Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAnpario Regulatory News (ANP)

Share Price Information for Anpario (ANP)

Share Price is delayed by 15 minutes
Get Live Data
520.00    5.00 (0.97%)
Bid:
510.00
Ask:
530.00
Spread: 20.00 (3.922%)
Market Cap: £85.47m
ANP Live PriceLast checked at - London Stock Exchange

Intraday Anpario Share Chart

AGM Statement

25 Jun 2024 07:00

RNS Number : 6762T
Anpario PLC
25 June 2024
 
Anpario plc("Anpario", "Group" or the "Company")

 

AGM Statement

 

 

Anpario plc, the independent manufacturer of natural sustainable animal feed additives for health, nutrition and biosecurity, is holding its AGM later today, at which Matthew Robinson, Chairman, will make the following statement:

 

"The Group has delivered a strong sales performance and a corresponding improvement in profit in the first half of the year as the global agriculture market continues to improve and we are confident of achieving market expectations for the full year. There are still challenges to navigate and as highlighted at the time of our 2023 full year results announcement on 20 March 2024, we expected individual territory performance to be variable. In contrast to the strong first half performances last year in the United States and Australia, both territories have experienced weaker trading in the current period. However, all other regions have delivered strong sales growth with notable performances from Asia Pacific, Middle East and Africa and South America, demonstrating the resilience afforded by our geographic diversity.

 

The Group's business development initiatives are centred around expanding in the ruminant and aquaculture sectors as well as working with several partners in pet food where we can offer natural sustainable solutions. Our unique water-soluble phytogenic product Orego-Stim® Forte, for aquatic species, continues to show excellent field trial results, especially for inhibiting the growth of Vibrio species of bacteria in the absence of antibiotics. As such we are experiencing strong interest for this product from across the aquaculture industry.

 

Raw material prices have stabilised and together with increased volumes through our highly automated production facility we are delivering improved gross margins and profitability. Our cash position has improved further since the year end, with a balance of £12.2m as at 31 May 2024, giving us a strong financial position with which to continue to grow the business, both organically and through acquisitions, should the right opportunities arise."

 

The Company's interim results for the six months period ended 30 June 2024 are expected to be announced on 11 September 2024. 

 

 

 

Enquiries

 

Anpario plc

Richard Edwards, Chief Executive Officer

+44(0)7776 417 129

Marc Wilson, Group Finance Director

+44(0)1909 537 380

Shore Capital

 

(Nominated Adviser and Broker)

+44 (0) 20 7408 4090

Stephane Auton

Corporate Advisory

David Coaten

Tom Knibbs

Henry Willcocks

Corporate Broking

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
AGMFLFLTREISFIS
Date   Source Headline
12th Jul 20171:43 pmRNSDirector/PDMR shareholding and Total Voting Rights
30th Jun 20177:00 amRNSDirector/PDMR Shareholding
29th Jun 201712:06 pmRNSResult of AGM
29th Jun 20177:00 amRNSAGM Statement
19th Jun 20172:15 pmRNSHolding(s) in Company
7th Jun 20174:22 pmRNSHolding(s) in Company
5th Jun 201710:20 amRNSDividend date
26th May 20171:53 pmRNSNotice of AGM
23rd May 20173:31 pmRNSHolding(s) in Company
9th May 20175:21 pmRNSDirector/PDMR Shareholding
23rd Mar 20177:00 amRNSDirector Declaration
10th Mar 20177:00 amRNSDirector/PDMR Shareholding
8th Mar 20177:00 amBUSFinal Results
1st Mar 20178:39 amRNSHolding(s) in Company
23rd Feb 20177:00 amRNSReplacement Announcement
15th Feb 20174:29 pmRNSHolding(s) in Company
15th Feb 20172:35 pmRNSBLOCK LISTING SIX MONTHLY RETURN
3rd Feb 20177:00 amRNSAcquisition
2nd Feb 20177:00 amRNSTrading Statement
1st Dec 20167:00 amRNSTotal Voting Rights
22nd Nov 20167:00 amRNSEmployee Share Plan and Directors' Dealing
6th Oct 201611:46 amRNSHolding(s) in Company
16th Sep 20164:36 pmRNSDirector/PDMR Shareholding and Share Plan Limits
14th Sep 20167:30 amBUSHalf-year Report
9th Sep 20163:21 pmRNSTotal Voting Rights
4th Aug 20163:33 pmRNSTotal Voting Rights
4th Aug 20163:32 pmRNSBlock listing Interim Review
6th Jul 20165:00 pmRNSDirector/PDMR Shareholding
6th Jul 20167:00 amRNSHolding(s) in Company
4th Jul 20163:38 pmRNSTotal Voting Rights
29th Jun 20165:17 pmRNSResult of AGM
28th Jun 20167:00 amRNSAGM Statement
13th Jun 20167:00 amRNSTotal Voting Rights
21st Apr 201612:05 pmRNSHolding(s) in Company
8th Mar 20167:00 amBUSFinal Results
29th Feb 20164:59 pmRNSBlocklisting Interim Review
1st Feb 20167:00 amRNSTrading Statement
13th Jan 201611:00 amRNSBoard and Management Changes
3rd Dec 201511:19 amRNSHolding(s) in Company
1st Dec 20157:00 amRNSTotal Voting Rights
21st Sep 20155:23 pmRNSDirector/PDMR Shareholding
16th Sep 20154:55 pmRNSDirector/PDMR Shareholding
16th Sep 20157:00 amBUSHalf-yearly Report
31st Jul 20153:40 pmRNSTotal Voting Rights
31st Jul 20153:39 pmRNSBlocklisting Interim Review
25th Jun 20151:21 pmRNSResult of AGM
25th Jun 20157:00 amRNSAGM Statement
2nd Jun 20152:49 pmRNSHolding(s) in Company
27th May 20158:38 amRNSDirector/PDMR Shareholding
22nd Apr 20151:52 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.